Pfreundschuh M, Poeschel V, Zeynalova S et al.: Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the DSHNHL. J Clin Oncol in press, 2014;

Murawski N, Pfreundschuh M, Zeynalova S et al.: Optimization of rituximab for the treatment of DBCL (I): Dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol in press, 2014;

Bittenbring J, Neumann F, Altmann B et al.:  Vitamin D deficiency mpairs rtiuximab-mediated cellular cytotoxicity and outcome of DLBCL patients treated with, but not without rituximab . J Clin Oncol in press, 2014;

Held G, Murawski N, Ziepert M et al.: Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol32:1112-1118, 2014;

Glass B, Hasenkamp J, Wulf G et al.: Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 15:757-766, 2014;

Hohloch K, Zwick C, Ziepert M et al.: Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. Springer plus 3:5, 2014;

Seymour JF, Pfreundschuh M, Trneny M et al.: R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica, 2014;

Meissner J, Tichy D, Dietrich S et al.: Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma. Br J Haematol, 2014;

Assmann G, Shihadeh K, Poeschel V et al.: Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study. PLoS One 9:e88177, 2014;